Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal down50.300 -1.200 (-2.330%)

06/12/2021 10:46

Junshi Bio: FDA expands EUA of etesevimab & bamlanivimab

[ET Net News Agency, 6 December 2021] Shanghai Junshi Biosciences Co., Ltd. (01877)
said the United States Food and Drug Administration (FDA) has expanded the emergency use
authorization (EUA) for etesevimab (JS016/LY-CoV016) and bamlanivimab (LY-CoV555)
administered together (therapy) to include certain high-risk pediatric patients from birth
to under 12 years old for the treatment of mild to moderate COVID-19 as well as
post-exposure prophylaxis.
The therapy has been the first and only authorized neutralizing antibody therapy for
emergency use in COVID-19 individuals under the age of 12, and offers treatment and
prevention options to high-risk individuals of any age. (RC)

Remark: Real time quote last updated: 25/01/2022 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2022 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.